ONCOCROSS
27.5.2024 15:01:26 CEST | Business Wire | Press release
Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform.
Under this contract, the two companies will join research efforts to identify and verify development possibilities for new indications for the 'first-in-class' drug pipeline that JW Pharmaceutical is developing in the area of anticancer and regenerative medicine.
For this purpose, Oncocross’s proprietary AI platform RAPTOR AITM will be utilized. RAPTOR AITM is an AI drug development platform that screens the optimal or additional indications for drug candidates or existing drugs. The platform provides AI capabilities necessary for pharmaceutical companies' new drug development, resulting in higher accuracy, reduced cost, and shorter development time compared to traditional methods.
Previously, the two companies signed a joint research agreement to identify new indications for drug candidates in 2022. Through this joint research, JW Pharmaceutical has secured positive data on expanding an orphan disease indication for the new drug candidate and is establishing a follow-up development plan.
Having previously verified the RAPTOR AITM technology, JW Pharmaceutical once again expects to reduce the time required for new indication screening and increase the probability of success in clinical studies for the 'first-in-class' drug pipelines.
JW Pharmaceutical said, “The level of innovation we are focusing on requires high R&D capabilities and substantial costs and time to discover new drug candidates and indications,” adding, “We will continue to pursue diverse partnerships with innovative local and global biotech companies that possess new technologies such as Oncocross.”
Dr. Yirang Kim, CEO of Oncocross commented, "This follow-on collaboration is significant in the sense that the utility and commercial value of RAPTOR AITM has been recognized in the market.” He further added, “We will continue to do our best to set examples of collaboration between large pharmaceutical companies and biotech in the AI drug development field.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528528566/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
IQOSand Devialet Introduce “Soundsorial Design” Collaboration20.4.2026 10:00:00 CEST | Press release
Exhibition and capsule collection drop at Milan Design Week 2026 Philip Morris International (NYSE: PM) today announced a collaboration between IQOS – the number 1 tobacco heating system1, and Devialet – the French acoustic engineering company, launching “Soundsorial Design” at Milan Design Week 2026. The immersive exhibition is an ethereal landscape of water and light, where sound, movement, and voice become visible across an ever‑changing immersive canvas. A space to push experiential boundaries, where visitors are invited to explore their own frequency as sound transforms into sight.The collaboration celebrates self-expression while connecting a community of over 35 million IQOS users who moved away from cigarettes. Devialet’s mission to give sound its rightful place in our lives, achieved through acoustic breakthroughs, meets IQOS’s bold spirit of being forever curious – the force that pushes the brand to continuously innovate and explore new technologies for a better future. Two p
Europe’s Technology Services Market Accelerates in Q1 on Higher Demand for AI: ISG Index™20.4.2026 10:00:00 CEST | Press release
Combined market up 30%, to record US $12.2 billion, fueled by strong AI-driven IaaS growth Demand for technology services in Europe continued to accelerate in the first quarter, driven by strong demand for the cloud-based infrastructure services needed to power AI, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, shows. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market (both managed services and cloud-based as-a-service) climbed 30 percent in the first quarter, to a record US $12.2 billion. Sequentially, the market was up 12 percent from its previous high in the fourth quarter. Over the last seven quarters, EMEA’s combined market has risen by double-digits in six of them, averaging 22 percent year-on-year growth in that span. “Europe has clearly turned the corner, as the region
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom